Our findings suggest that angiomyolipomas fit this general model of pediatric tumor development, with few somatic mutations and a single critical target of inactivating mutation (in the case of angiomyolipoma, this is usually TSC2 and less commonly TSC1) that initiates and drives tumor development. The gene discussed is TSC2; the disease is neoplasm.